



PTO/SB/21 (09-04)

CT FY

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/814,490
Filing Date	March 29, 2004
First Named Inventor	Johnson, Jr.
Art Unit	2861
Examiner Name	as yet unknown
Attorney Docket Number	010083.02


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Supplemental Application Data Sheet <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) listed below: Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Kosan Biosciences, Inc.		
Signature			
Printed name	Yuan Chao		
Date	April 28, 2005	Reg. No.	32,118

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Nancy Impey	Date	April 28, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Appl'n of: Johnson, Jr.

Appl'n No.: 10/814,490

Group Art Unit: 2861

Title: DEVICES, METHODS, AND
COMPOSITIONS TO PREVENT
RESTENOSIS

Att'y Ref. No.: 010083.02

Filed: March 29, 2004

Examiner: (as yet unknown)

Mailing Address: Kosan Biosciences, Inc.
3832 Bay Center Place
Hayward, CA 94545Information Disclosure Statement

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement (“IDS”) is submitted to the Patent Office in accordance with the duty of candor and good faith under 37 CFR §1.56. The Examiner is requested to consider the cited information in the examination of this application.

The cited information is listed in the accompanying list (2 sheets total), submitted in duplicate. Each item of information is identified there by a unique “Item No.” (A01, A02, ..., B01, ..., etc.) The Examiner is requested to return an initialed and signed copy of the list, indicating whether each item of cited information has been considered or not.

Copies of US patents and published applications are not being furnished with this IDS, in accordance with the revisions to 37 CFR §1.98(2) as announced in the Federal Register, vol. 69, no. 182, pp. 56482-56547 (Sep. 21, 2004). If the Examiner should need copies of any of such patents or patent applications, they will be provided upon request.

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date given below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of person signing certificate: Nancy Impey
 Signature: Nancy Impey Date: 4/28/05

The Examiner's attention is particularly drawn to the following items concerning a stent or other implantable medical device that releases a drug, wherein:


- The drug is identified as an "epothilone" generically or a specific epothilone (*e.g.*, "epothilone A", "epothilone D"): A05, A06, A07, A28, A10, A15, A22, A29, A30, A32, A33, B04.
- The drug is identified as "geldanamycin" or a derivative or analog thereof (*e.g.*, "17-allylamino-17-demethoxygeldanamycin" ("17-AAG")): A13, A25, A30, B02, B03.
- The drug is identified as "rapamycin" (synonym "sirolimus") or a derivative or analog thereof (*e.g.*, "everolimus", "rapalog"): A01, A03, A08, A12, A13, A16, A17, A18, A19, A20, A30, A32, B02, B03.

The citation of a particular item of information is not intended to be, and should not be construed as, an admission that such item of information is material to patentability as defined in 37 CFR §1.56 or qualifies as "prior art" within the meaning of applicable law. The materiality and "prior art" status of any item of information is a matter to be resolved during examination.

Consideration of the cited information in the examination of this application is respectfully requested.

Respectfully submitted,

Apr. 28, 2005
Date


Yuan Chao
Reg. No. 32,118
Telephone (510) 731-5156
Facsimile (510) 731-5143

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION: LIST OF ART CITED		<i>Docket No.</i> 010083.02	<i>Application Number:</i> 10/814,490
		<i>First Named Applicant:</i> Johnson, Jr.	
		<i>Filing Date:</i> Mar. 29, 2004	<i>Group Art Unit:</i> 2861

O I P E
MAY 02 2005
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

US PATENTS AND PUBLISHED APPLICATIONS					
Examiner Initial	Item No.	Document Number	Issue or Publication Date	Name	Cited at (if cited in specification)
	A01	US 5,288,711	1994	Wright <i>et al.</i>	
	A02	US 5,609,629	1997	Fearnott <i>et al.</i>	
	A03	US 5,665,728	1997	Morris <i>et al.</i>	
	A04	US 6,242,469 B1	2001	Danishefsky <i>et al.</i>	
	A05	US 6,419,692 B1	2002	Yang <i>et al.</i>	
	A06	US 6,495,579 B1	2002	Hunter	
	A07	US 6,544,544 B2	2003	Hunter <i>et al.</i>	
	A08	US 6,585,764 B2	2003	Wright <i>et al.</i>	
	A09	US 6,670,168 B1	2003	Katz <i>et al.</i>	
	A10	US 6,689,803 B2	2004	Hunter	
	A11	US 6,786,922 B2	2004	Schaeffer	
	A12	US 2002/0098278 A1	2002	Bates <i>et al.</i>	
	A13	US 2002/0127263 A1	2002	Carlyle <i>et al.</i>	
	A14	US 2002/0143048 A1	2002	Kinsella <i>et al.</i>	
	A15	US 2003/0023082 A1	2003	Ashley <i>et al.</i>	
	A16	US 2003/0050692 A1	2003	Sirhan <i>et al.</i>	
	A17	US 2003/0060877 A1	2003	Falotico <i>et al.</i>	
	A18	US 2003/0099712 A1	2003	Jayaraman	
	A19	US 2003/0114450 A1	2003	Santi <i>et al.</i>	
	A20	US 2003/0130206 A1	2003	Koziak <i>et al.</i>	
	A21	US 2003/0139800 A1	2003	Campbell	
	A22	US 2003/0157187 A1	2003	Hunter	
	A23	US 2003/0187493 A1	2003	Campbell <i>et al.</i>	

<i>Examiner</i>	<i>Date considered</i>
-----------------	------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to the applicant.

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION: LIST OF ART CITED		<i>Docket No.</i> 010083.02	<i>Application Number:</i> 10/814,490
<i>First Named Applicant:</i> Johnson, Jr.			
<i>Filing Date:</i> Mar. 29, 2004		<i>Group Art Unit:</i> 2861	

US PATENTS AND PUBLISHED APPLICATIONS					
Examiner Initial	Item No.	Document Number	Issue or Publication Date	Name	Cited at (if cited in specification)
	A24	US 2003/0204238 A1	2003	Tedeschi	
	A25	US 2003/0207856 A1	2003	Tremble <i>et al.</i>	
	A26	US 2003/0232122 A1	2003	Chappa <i>et al.</i>	
	A27	US 2004/0073284 A1	2004	Bates <i>et al.</i>	
	A28	US 2004/0076672 A1	2004	Hunter <i>et al.</i>	
	A29	US 2004/0152708 A1	2004	Li <i>et al.</i>	
	A30	US 2004/0172127 A1	2004	Kantor	
	A31	US 2004/0243214 A1	2004	Farrell <i>et al.</i>	
	A32	US 2005/0060028 A1	2005	Horres <i>et al.</i>	
	A33	US 2004/0076672 A1	2004	Hunter <i>et al.</i>	
	A34	US 6,284,781 B1	2001	Danishefsky <i>et al.</i>	
	A35	US 2004/0225077 A1	2004	Gravett <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Item No.	Document Number	Date	Country	Translation enclosed?	Cited at (if cited in specification)
	B01	WO 00/44443 A2	2000	PCT	n/a	
	B02	WO 2003/039612 A1	2003	PCT	n/a	
	B03	WO 2004/010900 A1	2004	PCT	n/a	
	B04	WO 2004/052361 A1	2004	PCT	n/a	
	B05	WO 2005/030934 A2	2005	PCT	n/a	

****** END OF LIST ******

<i>Examiner</i>	<i>Date considered</i>
-----------------	------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to the applicant.